Endoscopic recurrence within 2 years of ileocolic resection

What is known

• A retrospective ileocolic-resection cohort found endoscopic recurrence (Rutgeerts ≥i2) in 59.5% of patients at a mean of 9 months post-op. ¹
• Endoscopic recurrence, defined using the Rutgeerts score, occurs in 30% - 90% of patients at the neoterminal ileum within 12 months of surgery and almost universally by 5 years. ⁴
• A meta-analysis of 16 randomised trials of postoperative prophylaxis, cited by that technical review, put endoscopic recurrence in the placebo arms at 50% (95% CI 28 - 73), with considerable unexplained heterogeneity that baseline risk factors could not account for. ⁴
• At about two years, a prospective cohort of 61 patients found morphological recurrence, assessed by ileocolonoscopy or MR enterography, in 27 patients (44.3%), most of whom were asymptomatic. ²
• In a randomised trial of 63 patients, Rutgeerts-defined endoscopic recurrence at 102 weeks was 17/32 (53%) with routine early azathioprine prophylaxis and 18/31 (58%) with endoscopy-guided therapy (RR 0.91, 95% CI 0.59 - 1.42). ⁴
• Endoscopic recurrence typically precedes clinical recurrence, and ileocolonoscopy at 6 - 12 months is the recommended surveillance modality. ^2–4

What is unknown / caveats

• No pooled estimate is anchored specifically at 24 months: the pooled placebo-arm figure is drawn from prophylaxis trials with differing follow-up, and the 24-month figures above rest on two small single studies
• The two-year figures are not directly comparable: one counts morphological recurrence on ileocolonoscopy or MR enterography, the other counts Rutgeerts-defined endoscopic recurrence in trial arms that received either routine prophylaxis or endoscopy-guided treatment, so neither describes untreated natural history
• The 59.5% single-cohort figure is a small (n=42) retrospective series
• Rates depend on Rutgeerts threshold, endoscopy timing, and use of postoperative prophylaxis

References

1. [No authors listed]. Updating predictors of endoscopic recurrence after ileocolic resection for Crohn disease. Turk J Gastroenterol. 2017;28(4):260-265. PMID: 28594329.

2. [No authors listed]. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. Inflamm Bowel Dis. 2019;25(10):1681-1691. PMID: 30925193.

3. [No authors listed]. Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated with Reduced Surgical Recurrence: Editorial by Coffey et al. J Crohns Colitis. 2018;12(10):1137-1138. PMID: 30137343.

4. [No authors listed]. American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. Gastroenterology. 2017;152(1):277-295.e3. PMID: 27840073.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.